Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trialJinjing Liu, Xiaofeng Zeng, Jingbo Su et al.|Annals of the Rheumatic Diseases|2025Cited by 17
Beyond the Mirror: Future Orientation Reduces Self-ObjectificationQinzi Li Mo, Wenqian Lu, Baoyu Bai et al.|Archives of Sexual Behavior|2025Cited by 1